Urology News and Research

Latest Urology News and Research

FDA approves LONSURF for treatment of patients with metastatic colorectal cancer

Taiho Oncology, Inc. (U.S.), a subsidiary of Taiho Pharmaceutical Co., Ltd. (Japan), today announced that the U.S. Food and Drug Administration approved LONSURF (trifluridine and tipiracil), formerly known as TAS-102, for the treatment of patients with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if RAS wild-type, an anti-EGFR therapy.

22 Sep 2015

Family history: The most vital risk factor for prostate cancer

Family history is the most critical risk factor for prostate cancer. Men are more at risk if they had a father or brother with prostate cancer.

22 Sep 2015

USPSTF recommendation against regular PSA screening may delay diagnosis of prostate cancer

The U.S. Preventive Services Task Force recommendation against regular prostate specific antigen (PSA) screening for prostate cancer is controversial. While it may reduce the risk of over diagnosis and overtreatment, the reduction in intermediate and high risk cancer diagnoses raises concern because of the potential for delayed diagnoses of important cancers in men who may benefit from treatment, according to investigators reporting in The Journal of Urology.

22 Sep 2015

Active surveillance ‘viable option’ for SRM management

US researchers find no significant difference in survival outcomes between patients with small renal masses who opt for active surveillance and those who choose immediate treatment.

17 Sep 2015

Coloplast announces launch of most compact catheter for men in the U.S.

Coloplast announced the U.S. launch of SpeediCath Compact Male, the most compact catheter for men, designed so users can do more. The new product is less than half the size of a standard male catheter and may be stored, carried, used and disposed of more discreetly.

15 Sep 2015

African-American men at increased risk of dying of prostate cancer than Caucasian men

African-American men are more than twice as likely to die of prostate cancer compared to Caucasian men. World renowned robotic prostate surgeon, Dr. David Samadi, encourages them to have a complete family history of prostate cancer as part of their prevention plan.

15 Sep 2015

Researchers find key cellular enzyme that could be effective drug target for urologic cancer cells

Researchers at the SUNY Upstate Medical University have found that a key cellular enzyme, c-Abl, could be an effective drug target in cancer cells for urologic cancers, such as prostate and kidney.

11 Sep 2015

Allergan settles patent litigation with Amneal related to NAMENDA XR extended release capsules

Allergan plc, today announced that its subsidiaries Forest Laboratories, LLC and Forest Laboratories Holdings, Ltd., along with Adamas Pharmaceuticals, Inc., have entered into a settlement agreement with Amneal Pharmaceuticals LLC and related companies and subsidiaries.

10 Sep 2015

Allergan enters into agreement to acquire Aquesys and its XEN45 program

Allergan plc, a leading global pharmaceutical company, and AqueSys, Inc. a private clinical stage medical device company focused on developing ocular implants that reduce intraocular pressure (IOP) associated with glaucoma, today announced that they have entered into an agreement under which Allergan will acquire AqueSys in an all-cash transaction.

4 Sep 2015

NxThera obtains FDA clearance for Rezūm System to treat BPH

NxThera, Inc., a medical device company pioneering the application of its Convective Water Vapor Energy (WAVE) platform technology to treat endourological conditions, is pleased to announce it has received FDA 510(k) clearance of the company's Rezūm System to treat BPH.

3 Sep 2015

Allergan announces positive results from AVYCAZ Phase III studies for treatment of cUTI

Allergan plc. today announced positive topline results from RECAPTURE 1 and 2, the pivotal Phase III studies evaluating the antibiotic AVYCAZ (ceftazidime-avibactam) as a treatment for adult hospitalized patients with complicated urinary tract infections (cUTI), including pyelonephritis.

2 Sep 2015

FDA approves Allergan's sNDA to update label for TEFLARO (ceftaroline fosamil)

Allergan plc today announced the U.S. Food and Drug Administration has approved the company's supplemental new drug application (sNDA) to update the label for TEFLARO (ceftaroline fosamil) for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI) and community-acquired bacterial pneumonia (CABP).

2 Sep 2015

Men with relatively unaggressive prostate tumors unlikely to develop metastatic prostate cancer

Men with relatively unaggressive prostate tumors and whose disease is carefully monitored by urologists are unlikely to develop metastatic prostate cancer or die of their cancers, according to results of a study by researchers at the Brady Urological Institute at Johns Hopkins, who analyzed survival statistics up to 15 years.

1 Sep 2015

Telesta Therapeutics receives FDA BLA Filing Notification for MCNA

Telesta Therapeutics Inc. announced today that it has received its BLA Filing Notification for MCNA from the U.S. Food and Drug Administration. This formal letter communicates that the FDA has completed its initial review of Telesta's Biologics License Application (BLA) submitted on June 29, 2015 and has accepted it for filing.

29 Aug 2015

Medeon Biodesign gets FDA clearance for new lens cleaning device

Medeon Biodesign, Inc., a Taiwan medical device company, is pleased to announce that the company has received U.S. Food and Drug Administration 510(k) clearance for ClickClean, a lens cleaning device.

25 Aug 2015

New research finds five different types of prostate cancer

New research has revealed that five different types of prostate cancer exist. How will this discovery change the outlook of prostate cancer screening? World renowned robotic prostate cancer surgeon, Dr. David Samadi, evaluates.

25 Aug 2015

PSMA PET imaging more precise than MR imaging for detection of high-grade prostate cancer lesions

A molecular imaging biomarker is able to detect fast-growing primary prostate cancer and distinguish it from benign prostate lesions, addressing an unmet clinical need. The new research, published in the July 2015 issue of The Journal of Nuclear Medicine, is significant for patients with suspected prostate cancer that has not been confirmed by standard biopsy.

21 Aug 2015

FDA accepts Allergan's resubmission of BOTOX sBLA for treatment of adults with upper limb spasticity

Allergan plc, a leading global pharmaceutical company today announced that the U.S. Food and Drug Administration has accepted the company's resubmission of its Supplemental Biologics License Application (sBLA) for BOTOX (onabotulinumtoxinA) for the treatment of adults with lower limb (involving ankle and toe muscles) spasticity in adults.

20 Aug 2015

STA inks license and commercialisation agreement with PharmaMar for APLIDIN (plitidepsin)

Australian biopharmaceutical company Specialised Therapeutics Australia has struck an exclusive license and commercialisation agreement with European pharmaceutical partner company PharmaMar to market and distribute the novel oncology drug APLIDIN (plitidepsin) in Australia and New Zealand.

20 Aug 2015

Telesta closes US$28.6 million in private placement financing

Telesta Therapeutics Inc. announced today that it has closed a private placement financing of US$28.6 million. This transaction was led by several prominent U.S. healthcare investors, including Consonance Capital Investors, Boxer Capital of Tavistock Life Sciences and Omega Funds. In addition, certain members of the senior management team and board of directors of Telesta participated in the transaction.

19 Aug 2015

Urology News and Research

Latest Urology News and Research

FDA approves LONSURF for treatment of patients with metastatic colorectal cancer

Family history: The most vital risk factor for prostate cancer

USPSTF recommendation against regular PSA screening may delay diagnosis of prostate cancer

Active surveillance ‘viable option’ for SRM management

Coloplast announces launch of most compact catheter for men in the U.S.

African-American men at increased risk of dying of prostate cancer than Caucasian men

Researchers find key cellular enzyme that could be effective drug target for urologic cancer cells

Allergan settles patent litigation with Amneal related to NAMENDA XR extended release capsules

Allergan enters into agreement to acquire Aquesys and its XEN45 program

NxThera obtains FDA clearance for Rezūm System to treat BPH

Allergan announces positive results from AVYCAZ Phase III studies for treatment of cUTI

FDA approves Allergan's sNDA to update label for TEFLARO (ceftaroline fosamil)

Men with relatively unaggressive prostate tumors unlikely to develop metastatic prostate cancer

Telesta Therapeutics receives FDA BLA Filing Notification for MCNA

Medeon Biodesign gets FDA clearance for new lens cleaning device

New research finds five different types of prostate cancer

PSMA PET imaging more precise than MR imaging for detection of high-grade prostate cancer lesions

FDA accepts Allergan's resubmission of BOTOX sBLA for treatment of adults with upper limb spasticity

STA inks license and commercialisation agreement with PharmaMar for APLIDIN (plitidepsin)

Telesta closes US$28.6 million in private placement financing

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Urology News and Research

Latest Urology News and Research

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in